What is the current stock price of Keros Therapeutics, Inc. (KROS)?

As of the latest market data, Keros Therapeutics, Inc. (KROS) is trading at $11.21. The stock has seen a loss of -10.29% today.

Does Keros Therapeutics, Inc. (KROS) pay a dividend?

Based on current data, Keros Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Keros Therapeutics, Inc.?

The current market capitalization of Keros Therapeutics, Inc. (KROS) is approximately unavailable.

KROS

Keros Therapeutics, Inc.·Healthcare

11.21

10.288%(−1.28)

Market Closed

11.79

5.221%(+0.58)

After Hours

Last Updated: — ET

52W L: $10.4152W H: $22.55

KROS NEWS

defenseworld.net

5d ago

JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS

JPMorgan Chase and Co. grew its position in shares of Keros Therapeutics, Inc. (NASDAQ: KROS) by 260.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 171,941 shares of the company's stock after buying an additional 124,287 shares during the

zacks.com

Apr 3

Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?

Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?

zacks.com

Mar 17

KROS Stock: What to Know About Rinvatercept in DMD

Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.

zacks.com

Mar 17

KROS: Is the Discount Book Value a Value Trap?

Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.

zacks.com

Mar 17

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.

defenseworld.net

Mar 13

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of “Hold” from Analysts

Keros Therapeutics, Inc. (NASDAQ: KROS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and five have issued a buy recommendation on the company.

Company Profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

163

IPO Date

2020-04-08

Beta

0.99

Websitewww.kerostx.com↗